The analysis of Group I mGluR localization in the mouth shows that mGluR5s, but not mGluR1s, are constitutively expressed in the trigeminal ganglion[8] and the masseter muscle[9]. During mandibular disorders characterized by pain in the temporomandibular joint (TMJ), inflammation is associated with mGluR5 upregulation that differentially modulates the expression of glutamate receptors in male rats, suggesting that the use of mGluR5 antagonists may be effective in the control of inflammation pain conditions[10].

Some studies concerned with the orofacial area, highlight the role of peripheral Group I mGluRs in interleukin-1beta (IL-1beta)-induced mechanical allodynia: the results show that rat treatment with mGluR5 antagonists, Methyl-6-(phenylethynyl)pyridine (MPEP) or SIB1893, 10 min prior to injection of IL-1beta suppress IL-1beta-induced mechanical allodynia[11-13].

Using immunofluorescence, mGluR5s have also been identified in the terminal region of axon innervating human dental pulp suggesting their involvement in receptor-mediated inflammatory nociception. Odontoblasts also express mGluR5s and may contribute to the transduction of nociceptive signals[14].

mGluR1s and mGluR5s have been studied in oral cancer as the mGluR family is known to participate in tumorigenesis[15]: mGluR5 has been detected in oral squamous cell carcinoma (SCC) using both human cell cultures and tissue specimens[16]. Furthermore, in addition to cell membrane localization, mGluR5s were found in cytoplasm; by using a specific agonist (DHPG) and antagonist (MPEP) the authors of this study concluded that these receptors may be involved in tumor progression and prognosis[16].

The expression of mGluR5 has been found in gastroesophageal vagal pathways in ferret, dog and mouse models and is also involved in the peripheral excitatory modulation of vagal afferent mechanosensitivity input[17-19]. The use of the mGluR5 antagonist, MPEP, has highlighted a decrease in reflux events through inhibition of transient lower sphincter relaxation (TLESR)[17,20]. Immunohistochemical localization of mGluR5 along the vago-vagal neural pathway has been found in human tissues indicating a potential peripheral effect of mGluR5 modulators[21]. In a trial involving a small group of patients with gastroesophageal reflux disease (GERD), use of ADX10059 a mGluR5 negative allosteric modulator, was associated with an improvement in clinical symptoms characterized by reduced acid reflux[22]. The results of randomized clinical trials on the effects of mGluR5 blockers in patients with GERD have confirmed and supported the reduction in TLESR and reflux events[23-25]. The poor tolerability (dizziness and nausea) associated with the use of ADX10059, has been reduced using a modified-release formulation or mono-therapy[23,24]. However, ADX10059 did not show to be significantly effective in refractory GERD patients[26]; furthermore, in a study on migraine, high incidence of hepatic transaminase was observed[27]. This effect appears to be related specifically to ADX10059 and not to the mGluR5-inhibiting mechanism of action[27], since the use of single doses of AZD2066, a non-competitive antagonist of mGluR5, in a small group of healthy subjects, has reduced the number of postprandial reflux episodes and appears to be better tolerated[25]. However, these preliminary results deserve further confirmation[27].

The study of mGluRs in the enteric nervous system (ENS), which is unique in its ability to mediate reflex activity independently of the CNS, has demonstrated that the Group I mGluRs are present in the submucous plexus of guinea-pig ileum; mGluR5-immunoreactivity has been found to be located exclusively on submucous neurons with other types of cells devoid of staining. In general, the immunolabeling was cytoplasmic, filling the perikarya and occasionally proximal dendrites. In addition, the staining intensity of the cell bodies varied: some were heavily stained, others only lightly. Immunoreactivities for mGluR1 and mGluR5 were also found in submucous plexus neurons of the jejunum and colon[28]. Other findings have demonstrated that Group I mGluRs are present in the ENS supporting their role in enteric reflexes and suggesting that the observed internalization might be a major mechanism for regulation of mGluR activity[29].

Because enteric neurons, like their equivalents in the CNS, are intimately associated with glial cells, one study has been carried out to test for glial mGluR5 expression in various species and assess whether enteric glia express mGluR5s and, if so, whether mGluR5 expression changes during intestinal inflammation[30]. mGluR5 expression has also been found on enteric glia in the ileum and colon of mice, rats and pigs; mGluR5 stimulation increases c-Fos and pERK1/2 activation specifically in enteric glia, establishing that mGluR5s are expressed in these cells. In addition, in this study, mGluR5 expression was shown to be decreased during chronic inflammation suggesting that mGluR5 signaling may be reduced in colitis[30]; enteric glia can be considered a target of the glutamatergic neurotransmitter system in the ENS and that changes in mGluR5 expression may play a modulatory role in inflammation[30].

mGluR5s are also involved in visceral pain: because mGluR5 antagonists inhibit colorectal distension (CRD)-evoked visceromotor (VMR) in rats, it has been concluded that mGluR5s participate in mediating mechanically evoked visceral nociception in the GI tract[31].

Recent evidence has demonstrated that in a model of total parenteral nutrition (TPN), glutamate supplementation prevents intestinal mucosal atrophy and a reduced epithelial barrier function (EBF) as compared with untreated animals[32]. It has further been reported that mGluR5s are involved in the effects of glutamate on EBF as 3-[(2-Methyl-4-thiazolyl)ethynyl]pyridine (MTEP), an mGluR5 antagonist, alleviates the decreased EBF observed in TPN animals treated with glutamate[32].

Inflammatory tongue pain is a more recently identified area of involvement for mGluR5s; extracellular signal-regulated kinase signaling (pERK signaling) is involved in the development of mechanical and heat hypersensitivity that appears to evolve in the inflamed tongue[33].

Assessment of mGluR5 localization has also been carried out on oral tongue cancer cells: HSC3 cells exhibit mGluR5; the use of the agonist DHPG increased tumor cell migration, invasion, and adhesion; this event has been shown to be reversed by the mGluR5 antagonist MPEP[16]. Similar findings - mGluR5 functions as an oncogene in solid cancers, including oral cancer - were found using B88 cells obtained from a patient with tongue cancer[34].

The presence of mGluRs in the liver was first suggested by Sureda et al[35], who showed that the competitive agonists, quisqualate and ACPD, stimulated polyphosphoinositide hydrolysis in primary rat hepatocytes. In this work, 100 μmol/L quisqualate and 100 μmol/L ACPD significantly increased the formation of [3H]InsP after 2 and 5 d of incubation, with respect to basal levels. This data suggested the activation of a Group I mGlu receptor, although at the time the subtype was not identified, since both quisqualate and ACPD were unspecific agonists. The presence of mGluR5s in rat hepatocytes was subsequently demonstrated for the first time by Storto et al[36], with mGluR5 protein and mRNA expression levels comparable to those observed in rat cerebral cortex. In this article, Storto et al[36] show that ACPD and quisqualate worsen cell injury in hepatocytes exposed to anoxic conditions; on the contrary MPEP, the selective negative allosteric modulator of mGluR5, protects hepatocytes against necrosis, suggesting that the activation of mGluR5s by endogenous glutamate is involved in the development of hypoxic injury[36]. In a subsequent study, Storto et al[36], demonstrated that the onset of hypoxic damage was significantly delayed in hepatocytes from mGlu5 receptor knockout mice, as well as in hepatocytes from wild type mice treated with 30 μmol/L MPEP. This study also observed substantial improvements in cell viability and intracellular free-radical production, with respect to wild type control hepatocytes[37].

It has been suggested that peripheral mGluRs could be activated by non-synaptic glutamate[38], probably synthesized from α-Ketoglutaric acid, a by-product of the Krebs cycle. During anoxia, blockade of the Krebs cycle causes accumulation of this intermediate, favoring its conversion into glutamate by various enzymes, such as glutamate dehydrogenase or aspartate transaminase[39]. Furthermore, the release of toxic glutamate concentrations in the CNS, in hypoxic conditions, has been variously attributed to increased activity in the mitochondrial enzyme glutaminase[40] or reduced activity of the ATP-dependent enzyme glutamine synthetase[41]. Similarly, Storto et al[36], had previously demonstrated an increase in glutamate release in hypoxic conditions in isolated rat hepatocytes. Subsequently, Storto et al[42] showed that the noncompetitive mGluR5 antagonists MPEP, SIB-1757 and SIB-1893 reduce ROS-induced toxicity in both in vitro and in vivo models. This study shows that selective blockade of mGluR5s reduce ROS production, malondialdehyde formation and thiol group oxidation, and improve hepatocyte viability in isolated hepatocytes treated with 0.5 mmol/L tert-butylhydroperoxide. Furthermore, in mice treated with acetaminophen (300 mg/kg), MPEP protects against toxicity, reducing the formation of ROS, due to acetaminophen-induced GSH depletion. The mechanism responsible for the protection against acetaminophen has not been clearly elucidated. However, in liver homogenates, Western Blot analysis has shown a significant acetaminophen-induced increase in inducible nitric oxide synthase (iNOS) expression, markedly reduced in mice co-injected with MPEP (20 mg/kg). Storto et al[42] also rules out the possibility of mGluR5 negative allosteric modulators (NAMs) providing protection through free-radical scavenging activity; somewhat curiously, MPEP maintains its beneficial effects even though it significantly depletes glutathione (GSH) in hepatocytes, whereas SIB-1893, another mGluR5 selective NAM, structurally different from MPEP, shows similar effects without reducing GSH stores. Based on these observations, Storto et al[42] have posited an indirect, GSH-independent effect of MPEP against acetaminophen toxicity. Indeed, the formation of GSH conjugates with mGluR5 ligands containing an acetylene group, has recently been demonstrated[43]. Since MPEP, but not SIB-1893, contains an acetylene bond, MPEP probably forms GSH-conjugates, which, in retrospect, explains the MPEP-induced GSH depletion. This observation further supports the hypothesis that MPEP protection may well occur without any interference with the GSH-mediated tert-buthylhydroperoxide metabolism, and cannot be entirely ascribed to reduced ROS formation[42]. Furthermore, Jesse et al[44] had found a decrease in liver injury and mortality in a hepatitis model induced by lipopolysaccharide and D-galactosamine using the same dose of MPEP reported by Storto et al[42]. Of note, this new study has reported a reduction in malondialdehyde formation and no changes in GSH-S-transferase after the administration of MPEP in agreement with the previous study by Storto et al[42].

Recently, hepatic mitochondrial dysfunctions have been observed in a rodent model of Parkinson disease. Rats with nigrostriatal degeneration induced by 6-hydroxydopamine intrastriatal administration have lower mitochondrial membrane potential and higher ROS production, with respect to sham operated animals[45]. In the same model, the administration of MPEP reduces ROS and improves ATP production with respect to Parkinsonian rats not treated with MPEP. This supports the hypothesis that MPEP may reduce ROS indirectly by improving mitochondrial efficiency rather than through direct ROS scavenging action[46].

The effects of inhibiting mGluR5 activity in hepatocellular carcinoma (HCC) have been analyzed using hepatocarcinoma cell lines and a xenograft model. Inactivation of mGluR5s with MPEP has been shown to cause inhibition of cell growth, migration, and invasion of HepG2 and Bel-7402 cells. Moreover, inhibition of tumor growth and potential metastasis of HCC has also been found in nude mice. Furthermore, mGluR5-mediated extracellular signal-regulated kinase (ERK) phosphorylation has been shown to be partially involved in cell growth and migration, as found by stimulation of (S)-3,5-Dihydroxyphenylglycine (DHPG), an agonist of the mGluR5 and blockade of MPEP and U0126, an inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (MEK)[47].

Using RT-PCR and immunoblotting analysis, one study has detected mGluR5s in rat and human islets of Langerhans whereas mGluR1s were not found[48]. The treatment of pancreatic beta cells, MIN6, with a specific Group I agonist DHPG, stimulates insulin release at low glucose concentrations (3-10 mmol/L). This, however, is absent in the presence of high concentrations of glucose (25 mmol/L). A subsequent study has demonstrated that anti-mGluR5 antibodies do not immunostain any islet cells, but do immunostain synaptic terminals and blood vessels in the pancreas[49].

Moving from these findings, Storto et al[5], have confirmed that beta-cells express mGluR5s and have reported that these receptors are found not just in the cell surface but also in insulin-secreting granules. The endogenous activation of mGluR5s appears to be permissive to glucose-stimulate Ca²⁺ release and insulin secretion. The study showed that the use of mGluR5 agonists (L-glutamate, quisqualate or DHPG) act extracellularly involving no changes in Ca²⁺ concentration or insulin secretion in pancreatic beta-cells. On the contrary, treatment with MPEP, a highly lipophilic drug and selective antagonist of mGluR5, or the use of mice lacking mGluR5 showed a blunted insulin response to glucose[5]. Thus, drugs such as mGluR5 modulators, under development for neurologic and psychiatric disorders, may also affect glucose homeostasis.